The pelvic congestion syndrome market is expected to gain growth at a potential rate of 5.70% in the forecast period of 2021 to 2028. The increase in the prevalence of pelvic organ prolapsed is the factor responsible for the market growth.

Request For a Sample Copy of This Report @

Pelvic congestion syndrome is a type of condition which leads to the pain in the pelvic region. This pain generally occurs due to problems in the veins present near the pelvic area. It is a common gynecological condition in women leading to severe chronic pelvic pain. The cause of pelvic congestion syndrome usually involves endometriosis, pelvic inflammatory disease, pelvic varicosities among others.

The rapid rise in the genital cancer burden is expected to accelerate the market growth in the forecast period of 2021 to 2028. Likewise, the rapid development of targeted drugs to treat ovarian cancers to fuel pelvic congestion syndrome treatment and rise in the healthcare spending are also predictable to enhance the pelvic congestion syndrome market growth. Furthermore, the rise in the need for non-invasive therapies and rise in the percutaneous trans catheter embolization are also projected to drive the market growth rate.

In addition, the technological advancements for effective treatment and procedures and rapid advances in medical sciences are likely to create various new opportunities that will impact this pelvic congestion syndrome market growth in the forecast period of 2021 to 2028.

North America leads the pelvic congestion syndrome market due to rapid advancement in technology, improvement in the healthcare facilities and better infrastructure. Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028 because of the rapid rise in prevalence of pelvic congestion syndrome.

The major players covered in the pelvic congestion syndrome market report are Novartis AG, Sanofi, Tolmar Pharmaceuticals, Inc., Actiza Pharmaceutical Private Limited, Pfizer, Inc., AbbVie Inc., GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Bayer AG, AstraZeneca, Indivior PLC, Takeda Pharmaceutical Company Limited and Fresenius Kabi USA among other domestic and global players.

About Data Bridge Market Research, Private Ltd

Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”


Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475